Takeda Pharmaceutical (TAK) Return on Capital Employed (2019 - 2026)

Takeda Pharmaceutical's Return on Capital Employed history runs 8 years deep, the most recent figure standing at 1.5% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 723.0% year-over-year to 1.5% in Q1 2026; TTM through Mar 2026 was 1.5%, a 723.0% decrease from a year earlier, with the FY2026 full-year figure at 0.05%, down 267.0% from the prior year.
• Return on Capital Employed slipped to 1.5% in Q1 2026 per TAK's latest filing, from 3.22% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 7.1% in Q3 2023 and bottomed at 1.5% in Q1 2026.
• The 5-year median for Return on Capital Employed is 5.85% (2025), against an average of 5.44%.
• Across the five-year window, Return on Capital Employed soared 206 bps in 2022 and plunged 723 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 6.02% in 2022, then advanced by 16 bps to 6.99% in 2023, then decreased by 24 bps to 5.33% in 2024, then slumped by 40 bps to 3.22% in 2025, then sank by 146 bps to 1.5% in 2026.
• Per Business Quant, the three latest TAK Return on Capital Employed figures stand at 1.5% (Q1 2026), 3.22% (Q4 2025), and 5.85% (Q3 2025).